Emisphere Reports Positive Clinical Results for Its Oral Drug Delivery Technology in Appetite Suppression Study

Emisphere Reports Positive Clinical Results for Its Oral Drug Delivery Technology in Appetite Suppression Study

CEDAR KNOLLS, N.J., Sep 17, 2010 (GlobeNewswire via COMTEX News Network) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that a clinical study found that the company's proprietary oral SNAC (Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") additive, in combination with two digestive hormones, was successful in reducing food intake and increasing satiety in healthy male subjects. The study was published in the August 18, 2010 online edition of the American Journal of Clinical Nutrition, the official publication of the American Society for Nutrition.

"This study provides validation of Emisphere's Eligen(R) Technology as one that can effectively facilitate the oral administration of therapeutic hormones with otherwise low oral bioavailability, thereby potentially eliminating major bottlenecks in drug development," noted Emisphere President and Chief Executive Officer Michael V. Novinski.

As described in the publication, 12 healthy male subjects were studied in a randomized double-blind, placebo-controlled 4-way crossover trial. Each subject received (in random order) 2.0 mg GLP-1, 1.0 mg PYY3-36, or 2.0 mg GLP-1, plus 1.0 mg PYY3-36.

Researchers observed that both digestive hormones, GLP-1 and PYY3-36, were rapidly absorbed from the gut, leading to plasma concentrations several times higher than those in response to a normal meal. GLP-1 alone, but not PYY3-36, significantly reduced total food intake. Co-administration of both hormones, taken in combination with SNAC in a single oral dose, reduced both total food intake by 21.5 percent, and increased fullness at meal onset (P <0.05). The 24-hour food intake was not affected by the single oral administration of the native hormones likely due to their short half-life.

The two digestive hormones utilized in the study are released naturally in proportion to ingested calories and signal "satiety," or fullness, to the brain. SNAC, which is based on Emisphere's Eligen(R) Technology, facilitates transport of these and other hormones with low oral bioavailability across biological membranes, such as those of the gastrointestinal tract. Emisphere had previously announced that SNAC had achieved Generally Recognized as Safe ("GRAS") status for its intended use in combination with nutrients added to food and dietary supplements.

About Emisphere Technologies, Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen(R) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(R) Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is: www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 25, 2010, Emisphere's Quarterly Report on Form 10-Q filed on May 17, 2010, and Emisphere's Quarterly Report on Form 10-Q filed on August 16, 2010 .

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Emisphere Technologies, Inc.

Emisphere Technologies, Inc.
Michael R. Garone, Chief Financial Officer
[email protected]
Karen Kelsch, Assistant Manager Communications
[email protected]

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX